Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics

Sarah A. Engelberth, Nadine Hempel, Magnus Bergkvist

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Ovarian cancer is the deadliest of all gynecological cancers and the fifth leading cause of death due to cancer in women. This is largely due to late-stage diagnosis, poor prognosis related to advanced-stage disease, and the high recurrence rate associated with development of chemoresistance. Survival statistics have not improved significantly over the last three decades, highlighting the fact that improved therapeutic strategies and early detection require substantial improvements. Here, we review and highlight nanotechnology-based approaches that seek to address this need. The success of Doxil, a PEGylated liposomal na-noencapsulation of doxorubicin, which was approved by the FDA for use on recurrent ovarian cancer, has paved the way for the current wave of nanoparticle formulations in drug discovery and clinical trials. We discuss and summarize new nanoformulations that are currently moving into clinical trials and highlight novel nanotherapeutic strategies that have shown promising results in preclinical in vivo studies. Further, the potential for nanomaterials in diagnostic imaging techniques and the ability to leverage nanotechnology for early detection of ovarian cancer are also discussed.

Original languageEnglish (US)
Pages (from-to)281-316
Number of pages36
JournalCritical reviews in oncogenesis
Volume19
Issue number3-4
DOIs
StatePublished - 2014

All Science Journal Classification (ASJC) codes

  • Cancer Research

Fingerprint Dive into the research topics of 'Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics'. Together they form a unique fingerprint.

  • Cite this